Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen unrecognized SBC Compensation Cost — RSUs (legacy) ($M) ($M)
Form 10-K Stock-Based Compensation Note (XBRL)
Latest, Q4 2017
304
Period ended Dec 31, 2017
Change on a year earlier
+0.3%
303 in Q4 2016
History
3 quarters
Since Q4 2015
Sources
3
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Unrecognized SBC Compensation Cost — RSUs (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2017 | Dec 31, 2017 | 304 | +0.3% | Form 10-K (filed 2018-02-13) ↗ |
| Q4 2016 | Dec 31, 2016 | 303 | -2.9% | Form 10-K (filed 2017-02-14) ↗ |
| Q4 2015 | Dec 31, 2015 | 312 | – | Form 10-K (filed 2016-02-16) ↗ |
Cite this data
StockData. (2026). Amgen Unrecognized SBC Compensation Cost — RSUs (legacy) ($M) ($M), quarterly Q4 2015–Q4 2017 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/sbc_unrec_rsu
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.